GBR-13098
GBR-13098 is a chemical compound that has been studied for its potential effects on the central nervous system. It is classified as a dopamine reuptake inhibitor, which means it can increase the levels of dopamine in the brain by preventing its reabsorption into neurons.
Chemical Properties[edit | edit source]
GBR-13098 is a member of the piperazine class of compounds. Its chemical structure includes a piperazine ring, which is a common feature in many psychoactive drugs. The exact molecular formula and structure of GBR-13098 are essential for understanding its pharmacological properties.
Pharmacology[edit | edit source]
As a dopamine reuptake inhibitor, GBR-13098 has been shown to increase extracellular levels of dopamine. This action is similar to that of other well-known stimulants, such as cocaine and methylphenidate. By inhibiting the dopamine transporter (DAT), GBR-13098 prevents the reuptake of dopamine into presynaptic neurons, thereby increasing the concentration of dopamine in the synaptic cleft.
Potential Therapeutic Uses[edit | edit source]
Research into GBR-13098 has primarily focused on its potential use in treating disorders related to dopamine dysregulation, such as Attention Deficit Hyperactivity Disorder (ADHD) and Parkinson's disease. However, its clinical application remains largely experimental.
Side Effects and Risks[edit | edit source]
Like other dopamine reuptake inhibitors, GBR-13098 may have a range of side effects. These can include increased heart rate, elevated blood pressure, and potential for abuse and addiction. Long-term use may lead to neurotoxicity and other adverse effects on the central nervous system.
Research and Development[edit | edit source]
GBR-13098 is still under investigation, and much of the research is preclinical. Studies have been conducted to understand its pharmacokinetics, pharmacodynamics, and potential therapeutic applications. Further research is needed to fully elucidate its safety profile and efficacy in humans.
See Also[edit | edit source]
- Dopamine reuptake inhibitor
- Central nervous system
- Dopamine
- Attention Deficit Hyperactivity Disorder
- Parkinson's disease
References[edit | edit source]
External Links[edit | edit source]
-
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
